Drug Profile
CRD 102 - Cardiora
Alternative Names: CRD-102 - Cardiora; CRD102Latest Information Update: 01 Jul 2019
Price :
$50
*
At a glance
- Originator Cardiora
- Class Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Heart failure
Most Recent Events
- 30 May 2019 Cardiora completes a phase 1b/IIa trial in Heart failure in USA (PO) (NCT03217331)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Heart-failure in Australia (PO, Capsule)
- 01 Feb 2018 Phase-I/II clinical trials in Heart failure (In adults, In the elderly) in USA (PO) (NCT03217331)